0460.HK
Sihuan Pharmaceutical Holdings Group Ltd. [0460.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
0460.HK Stock Summary
Top 10 Correlated ETFs
0460.HK
Top 10 Correlated Stocks
0460.HK
In the News
0460.HK Financial details
Company Rating
Neutral
Market Cap
4.83B
Income
936.03M
Revenue
5.84B
Book val./share
0.47
Cash/share
0.48
Dividend
0.04
Dividend %
6.07%
Employees
2.87K
Optionable
No
Shortable
Yes
Earnings
22 Mar 2024
P/E
-2.25
Forward P/E
-
PEG
-0.19
P/S
2.38
P/B
1.1
P/C
1.06
P/FCF
-9.48
Quick Ratio
1.89
Current Ratio
2.59
Debt / Equity
0.29
LT Debt / Equity
0.2
-
-
EPS (TTM)
0.1
EPS next Y
-
EPS next Q
-
EPS this Y
-564.6%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-5.65%
Revenue Q/Q
-27.9%
EPS Q/Q
-223.26%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-19%
ROE
-36%
ROC
-0.06%
Gross Margin
68%
Oper. Margin
-25%
Profit Margin
-106%
Payout
-57%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.49-0.88
52W High
-
52W Low
-
RSI
42
Rel Volume
0.76
Avg Volume
7.77M
Volume
5.89M
Perf Week
-1.92%
Perf Month
-10.53%
Perf Quarter
-16.39%
Perf Half Y
-20.31%
-
-
-
-
Beta
0.679
-
-
Volatility
0.02%, 0.03%
Prev Close
0%
Price
0.51
Change
2%
0460.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.31 | 0.3 | 0.26 | 0.32 | 0.23 | |
| Net income per share | 0.17 | -0.29 | 0.05 | 0.04 | -0.21 | |
| Operating cash flow per share | 0.19 | 0.15 | 0.02 | 0.07 | 0 | |
| Free cash flow per share | 0.16 | 0.1 | -0.03 | 0.01 | -0.04 | |
| Cash per share | 0.49 | 0.56 | 0.52 | 0.61 | 0.51 | |
| Book value per share | 1.32 | 1.01 | 0.97 | 0.88 | 0.51 | |
| Tangible book value per share | 0.93 | 1.02 | 1.02 | 0.92 | 0.54 | |
| Share holders equity per share | 1.32 | 1.01 | 0.97 | 0.88 | 0.51 | |
| Interest debt per share | 0.02 | 0 | 0.08 | 0.12 | 0.15 | |
| Market cap | 11.39B | 7.86B | 6.61B | 11.39B | 7.83B | |
| Enterprise value | 8.17B | 2.76B | 2.76B | 6.79B | 5.19B | |
| P/E ratio | 7.03 | -2.9 | 13.97 | 27.35 | -4.01 | |
| Price to sales ratio | 3.9 | 2.73 | 2.68 | 3.75 | 3.59 | |
| POCF ratio | 6.35 | 5.55 | 29.11 | 17.12 | 168.36 | |
| PFCF ratio | 7.44 | 8.57 | -23.65 | 177.24 | -21.99 | |
| P/B Ratio | 0.91 | 0.82 | 0.72 | 1.38 | 1.65 | |
| PTB ratio | 0.91 | 0.82 | 0.72 | 1.38 | 1.65 | |
| EV to sales | 2.8 | 0.96 | 1.12 | 2.24 | 2.38 | |
| Enterprise value over EBITDA | 4.26 | 1.7 | 3.87 | 7.29 | -22.65 | |
| EV to operating cash flow | 4.55 | 1.95 | 12.16 | 10.21 | 111.69 | |
| EV to free cash flow | 5.34 | 3.01 | -9.88 | 105.65 | -14.59 | |
| Earnings yield | 0.14 | -0.34 | 0.07 | 0.04 | -0.25 | |
| Free cash flow yield | 0.13 | 0.12 | -0.04 | 0.01 | -0.05 | |
| Debt to equity | 0.01 | 0 | 0.08 | 0.13 | 0.25 | |
| Debt to assets | 0.01 | 0 | 0.06 | 0.07 | 0.1 | |
| Net debt to EBITDA | -1.68 | -3.13 | -5.39 | -4.94 | 11.49 | |
| Current ratio | 2.57 | 2.79 | 2.62 | 3.09 | 2.59 | |
| Interest coverage | 284.42 | 286.35 | 59.12 | 5.76 | -2.54 | |
| Income quality | 1.11 | -0.51 | 0.48 | 1.6 | -0.02 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Payout ratio | 0.1 | -0.06 | 0.28 | 0.3 | -0.07 | |
| Sales general and administrative to revenue | 0.14 | 0.16 | 0.2 | 0.19 | 0.25 | |
| Research and developement to revenue | 0.16 | 0.21 | 0.36 | 0.34 | 0.49 | |
| Intangibles to total assets | 0.26 | 0.02 | 0.02 | 0.03 | 0.05 | |
| Capex to operating cash flow | -0.15 | -0.35 | -2.23 | -0.9 | -8.66 | |
| Capex to revenue | -0.09 | -0.17 | -0.21 | -0.2 | -0.18 | |
| Capex to depreciation | -1.35 | -1.93 | -2.01 | -2.15 | -1.19 | |
| Stock based compensation to revenue | 0 | 0 | 0.01 | 0.02 | 0.04 | |
| Graham number | 2.25 | 2.56 | 1.05 | 0.93 | 1.55 | |
| ROIC | 0.11 | 0.16 | 0.03 | 0.04 | -0.1 | |
| Return on tangible assets | 0.14 | -0.22 | 0.04 | 0.03 | -0.17 | |
| Graham Net | 0.26 | 0.32 | 0.25 | 0.15 | -0.11 | |
| Working capital | 3.53B | 4.04B | 3.96B | 5.24B | 4.02B | |
| Tangible asset value | 8.83B | 9.66B | 9.63B | 8.69B | 5.04B | |
| Net current asset value | 3.11B | 3.68B | 3.31B | 2.4B | 49.66M | |
| Invested capital | 0.01 | 0 | 0.08 | 0.13 | 0.25 | |
| Average receivables | 467.59M | 384.47M | 341.01M | 584.44M | 650.66M | |
| Average payables | 35.76M | 51.46M | 85.96M | 112.55M | 162.34M | |
| Average inventory | 264.54M | 355.36M | 452.74M | 605.59M | 661M | |
| Days sales outstanding | 59.65 | 37.05 | 57.74 | 93.59 | 87.39 | |
| Days payables outstanding | 25.22 | 40.73 | 70.51 | 71.39 | 108.29 | |
| Days of inventory on hand | 204.17 | 253.83 | 329.22 | 429.48 | 319.27 | |
| Receivables turnover | 6.12 | 9.85 | 6.32 | 3.9 | 4.18 | |
| Payables turnover | 14.47 | 8.96 | 5.18 | 5.11 | 3.37 | |
| Inventory turnover | 1.79 | 1.44 | 1.11 | 0.85 | 1.14 | |
| ROE | 0.13 | -0.28 | 0.05 | 0.05 | -0.41 | |
| Capex per share | -0.03 | -0.05 | -0.05 | -0.06 | -0.04 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.2 | 0 | 0.16 | 0 | 0.11 | |
| Net income per share | 0.06 | 0 | 0 | 0 | -0.01 | |
| Operating cash flow per share | 0.07 | 0 | 0.04 | 0 | 0 | |
| Free cash flow per share | 0.03 | 0 | 0.01 | 0 | 0 | |
| Cash per share | 0.56 | 0 | 0.56 | 0 | 0.48 | |
| Book value per share | 1.04 | 0 | 0.77 | 0 | 0.47 | |
| Tangible book value per share | 1.06 | 0 | 0.79 | 0 | 0.49 | |
| Share holders equity per share | 1.04 | 0 | 0.77 | 0 | 0.47 | |
| Interest debt per share | 0.09 | 0 | 0.12 | 0 | 0.14 | |
| Market cap | 26.15B | 0 | 10.26B | 0 | 6.71B | |
| Enterprise value | 22.34B | -4.6B | 6.34B | -2.63B | 4.31B | |
| P/E ratio | 10.69 | 0 | 63.52 | 0 | -33.81 | |
| Price to sales ratio | 13.71 | 0 | 7.01 | 0 | 6.36 | |
| POCF ratio | 42.52 | 0 | 27.37 | 0 | 237.08 | |
| PFCF ratio | 88.63 | 0 | 93.1 | 0 | -147.68 | |
| P/B Ratio | 2.66 | 0 | 1.41 | 0 | 1.52 | |
| PTB ratio | 2.66 | 0 | 1.41 | 0 | 1.52 | |
| EV to sales | 11.71 | 0 | 4.33 | 0 | 4.09 | |
| Enterprise value over EBITDA | 24.99 | 0 | 26.65 | 0 | 25.54 | |
| EV to operating cash flow | 36.31 | 0 | 16.92 | 0 | 152.32 | |
| EV to free cash flow | 75.7 | 0 | 57.55 | 0 | -94.89 | |
| Earnings yield | 0.02 | 0 | 0 | 0 | -0.01 | |
| Free cash flow yield | 0.01 | 0 | 0.01 | 0 | -0.01 | |
| Debt to equity | 0.08 | 0.13 | 0.16 | 0.25 | 0.29 | |
| Debt to assets | 0.06 | 0.07 | 0.08 | 0.1 | 0.11 | |
| Net debt to EBITDA | -4.27 | 0 | -16.46 | 0 | -14.21 | |
| Current ratio | 2.75 | 3.09 | 2.43 | 2.59 | 2.84 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1.01 | 0 | 9.28 | 0 | -0.57 | |
| Dividend Yield | 0 | 0 | 0.01 | 0 | 0.04 | |
| Payout ratio | 0 | 0 | 3 | 0 | -6.01 | |
| Sales general and administrative to revenue | 0.15 | 0 | 0.22 | 0 | 0.2 | |
| Research and developement to revenue | 0.17 | 0 | 0.31 | 0 | 0.28 | |
| Intangibles to total assets | 0.05 | 0.03 | 0.05 | 0.05 | 0.06 | |
| Capex to operating cash flow | -0.52 | 0 | -0.71 | 0 | -2.61 | |
| Capex to revenue | -0.17 | 0 | -0.18 | 0 | -0.07 | |
| Capex to depreciation | -2.09 | 0 | -1.48 | 0 | -0.6 | |
| Stock based compensation to revenue | 0.01 | 0 | 0.03 | 0 | 0.06 | |
| Graham number | 1.23 | 0 | 0.27 | 0 | 0.24 | |
| ROIC | 0.05 | 0 | -0.02 | 0 | 0.04 | |
| Return on tangible assets | 0.04 | 0 | 0 | 0 | 0 | |
| Graham Net | 0.27 | 0 | -0.01 | 0 | -0.14 | |
| Working capital | 4.56B | 5.24B | 4.38B | 4.02B | 4.14B | |
| Tangible asset value | 9.99B | 8.69B | 7.44B | 5.04B | 4.55B | |
| Net current asset value | 3.54B | 2.4B | 1.13B | 49.66M | -145.02M | |
| Invested capital | 0.08 | 0.13 | 0.16 | 0.25 | 0.29 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 39.39 | 0 | 50.88 | 0 | 41.09 | |
| Days payables outstanding | 25.42 | 0 | 32.73 | 0 | 54.5 | |
| Days of inventory on hand | 115.69 | 0 | 136.94 | 0 | 179.81 | |
| Receivables turnover | 2.28 | 0 | 1.77 | 0 | 2.19 | |
| Payables turnover | 3.54 | 0 | 2.75 | 0 | 1.65 | |
| Inventory turnover | 0.78 | 0 | 0.66 | 0 | 0.5 | |
| ROE | 0.06 | 0 | 0.01 | 0 | -0.01 | |
| Capex per share | -0.03 | 0 | -0.03 | 0 | -0.01 |
0460.HK Frequently Asked Questions
What is Sihuan Pharmaceutical Holdings Group Ltd. stock symbol ?
Sihuan Pharmaceutical Holdings Group Ltd. is a HK stock and trading under the symbol 0460.HK
What is Sihuan Pharmaceutical Holdings Group Ltd. stock quote today ?
Sihuan Pharmaceutical Holdings Group Ltd. stock price is $0.51 today.
Is Sihuan Pharmaceutical Holdings Group Ltd. stock public?
Yes, Sihuan Pharmaceutical Holdings Group Ltd. is a publicly traded company.
Company Profile
- Volume Average 7.77M
- Market Capitalization 4.83B
- Employee 2.87K
- CEO Dr. Weicheng Guo
- Headquarters Wan Chai,HK
- IPO Date 2010-10-28
-
Website
https://www.sihuanpharm.com 
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.
